Richard A. Kay
Bakewell, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 04, 2025
Disease-Modifying, Neuroprotective Effect of N-Acetyl-l-Leucine in Adult and Pediatric Patients With Niemann-Pick Disease Type C.
Journal: Neurology
Published: June 13, 2025
Trial of N-Acetyl-l-Leucine in Niemann-Pick Disease Type C.
Journal: The New England journal of medicine
Published: January 31, 2024
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.
Journal: EClinicalMedicine
Published: July 10, 2023
Assessing the Interchangeability of AVT02 and Humira® in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: April 10, 2023
Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 Gangliosidoses.
Journal: Neurology
Published: May 26, 2022
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST).
Journal: Expert opinion on investigational drugs
Published: February 02, 2022
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: October 07, 2021
Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial' [European Journal of Cancer, Volume 124 (January 2020) Pages 91-101].
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 11, 2020
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 24, 2019
DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment.
Journal: Science translational medicine
Published: September 21, 2017
Regional Ventilation Changes in the Lung: Treatment Response Mapping by Using Hyperpolarized Gas MR Imaging as a Quantitative Biomarker.
Journal: Radiology
Published: May 05, 2017
Last Updated: 09/26/2026